Loading
Prostate Cancer Treatment and Research / Prostate Cancer Diagnosis and Treatment / Economic and Financial Impacts of Cancer · Journal article
JAMA · August 13, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a retrospective analysis of national cancer center data examining how focal therapy for prostate cancer is being used across risk stratification categories. It characterizes patterns and identifies potentially inappropriate use but does not evaluate clinical outcomes or comparative efficacy.
Retrospective cohort study using national registry data. Patients with prostate cancer treated at US cancer centers participating in the National Cancer Database. Intervention: Focal therapy for prostate cancer. United States cancer centers.
Study characterizes focal therapy use patterns in low-, high-, and very high-risk prostate cancer disease Analysis describes patterns of use and identifies instances of inappropriate application across risk groups Examination includes intermediate-risk disease and temporal trends in adoption at US cancer centers
No clinical outcomes reported (oncologic control, toxicity, functional outcomes, or survival)
This descriptive analysis informs understanding of how focal therapy is currently being adopted in clinical practice but does not provide evidence on its efficacy, safety, or optimal patient selection. Clinicians should not use this to guide treatment decisions without outcome data.
Retrospective registry analysis describing focal therapy adoption patterns and characterizing use across risk groups, but providing no efficacy or safety outcomes to support clinical decision-making.
As stated by the source record.
This descriptive analysis informs understanding of how focal therapy is currently being adopted in clinical practice but does not provide evidence on its efficacy, safety, or optimal patient selection. Clinicians should not use this to guide treatment decisions without outcome data.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
This retrospective study uses data from the National Cancer Database to examine patterns and temporal trends in use of focal therapy for prostate cancer in US cancer centers; characterize inappropriate use in low-, high-, or very–high-risk disease; and describe intermediate-risk use.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.